CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Johnson & Johnson

JNJ
$649.59BMega Cap

Next catalyst

Phase 3December 2026

Nipocalimab

Arthritis, Rheumatoid

Get an email about JNJ's next catalysts

Track Johnson & Johnson (JNJ) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 6 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

7 upcoming, 1 past

Phase 3Next

Nipocalimab Phase 3 Est. Readout

December 2026~Nipocalimab201

Estimated primary completion for Nipocalimab trial (NCT05327114) in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Topline data typically follows completion by weeks to months.

Source
Phase 3

Nipocalimab Phase 3 Est. Readout (DAFFODIL)

February 2027~Nipocalimab655

Estimated primary completion for Nipocalimab trial (NCT06533098) in Thrombocytopenia, Neonatal Alloimmune. Topline data typically follows completion by weeks to months.

Source
Phase 2

Amivantamab IV Phase 2 Est. Readout (OrigAMI-1)

Q2 2027~QAmivantamab IV225

Estimated primary completion for Amivantamab IV trial (NCT05379595) in Advanced or Metastatic Colorectal Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 3

Daratumumab Phase 3 Est. Readout (MonumenTAL-3)

Q3 2027~QDaratumumab864

Primary completion for Daratumumab trial (NCT05455320) in Relapsed or Refractory Multiple Myeloma

Source
Phase 2

Teclistamab Phase 2 Est. Readout

August 2027~Teclistamab100

Estimated primary completion for Teclistamab trial (NCT05972135) in Multiple Myeloma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Amivantamab Phase 2 Est. Readout (PALOMA-2)

Q3 2027~QAmivantamab520

Estimated primary completion for Amivantamab trial (NCT05498428) in Carcinoma, Non-small-Cell Lung. Topline data typically follows completion by weeks to months.

Source
Phase 3

Nipocalimab Phase 3 Est. Readout (EPIC)

Q3 2027~QNipocalimab115

Estimated primary completion for Nipocalimab trial (NCT07217587) in Myasthenia Gravis. Topline data typically follows completion by weeks to months.

Source

How JNJ's past catalysts played out

Market Overview

Stock performance and key metrics

NYSEPharmaceutical PreparationsPharmaceutical🇺🇸North AmericaNEW BRUNSWICK138.2K employees

Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global.

Website
Drug Pipeline

Abiraterone acetate

Phase 3

Prostate Neoplasms

Lazertinib

Phase 3

Carcinoma, Non-Small-Cell Lung

PP6M

Phase 3

Schizophrenia

Etravirine

Phase 3

HIV Infections

tapentadol (CG5503) Immediate Release (IR)

Phase 3

Low Back Pain

Tapentadol (CG5503)

Phase 3

Arthralgia

CONCERTA (OROS methylphenidate hydrochloride)

Phase 3

Attention Deficit Disorder With Hyperactivity

OROS hydromorphone HCl

Phase 3

Pain

Peginterferon-alpha (PegIFNα-2a)

Phase 3

Hepatitis C, Chronic

MVA-BN-Filo

Phase 3

Hemorrhagic Fever, Ebola

Decitabine

Phase 3

Leukemia, Myeloid, Acute

Genetic: AAV5-hRKp.RPGR Intermediate Dose

Phase 3

X-Linked Retinitis Pigmentosa

Ad26.Mos4.HIV

Phase 3

Healthy

Icotrokinra

Phase 3

Crohn Disease

Remifentanil

Phase 3

Anesthesia

Pegylated interferon alfa-2a

Phase 3

Chronic Hepatitis C Virus (HCV) Infection

Guselkumab dose 1

Phase 3

Hidradenitis Suppurativa

Aticaprant

Phase 3

Depressive Disorder, Major

Milvexian

Phase 3

Acute Coronary Syndrome

Fentanyl 1-day transdermal patch (Titration Phase)

Phase 3

Pain

ER OROS paliperidone

Phase 3

Schizophrenia

Efgartigimod

Phase 3

Myasthenia Gravis

Erdafitinib

Phase 3

Advanced Solid Tumor

5-Flurouracil

Phase 3

Squamous Cell Carcinoma of Head and Neck

Group 2 ustekinumab

Phase 3

Crohn's Disease

ExPEC9V

Phase 3

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

NUCYNTA

Phase 3

Pain

Paliperidone palmitate (R092670)

Phase 3

Schizophrenia

paliperidone palmitate injection

Phase 3

Schizophrenia

TAR-210

Phase 3

Non-Muscle Invasive Bladder Neoplasms

Vinflunine

Phase 3

Urothelial Cancer

Guselkumab Dose 2

Phase 3

Colitis, Ulcerative

Ustekinumab IV

Phase 3

Colitis, Ulcerative

PP3M eq

Phase 3

Schizophrenia

Ad26.ZEBOV

Phase 3

Ebola Virus Disease

Bendamustine hydrochloride

Phase 3

Chronic Lymphocytic Leukemia

R331333 (referred to as JNS024 ER or CG5503)

Phase 3

Pain

Genetic: AAV5-hRKp.RPGR

Phase 3

X-Linked Retinitis Pigmentosa

Efavirenz

Phase 3

Human Immunodeficiency Virus-type 1 Infection

Pegylated interferon alfa-2a (PegIFNα-2a)

Phase 3

Hepatitis C, Chronic

Golimumab

Phase 3

Arthritis, Juvenile

Risankizumab

Phase 3

Crohn Disease

Nipocalimab

Phase 3

Arthritis, Rheumatoid

Rabeprazole sodium

Phase 3

Gastroesophageal Reflux

Telaprevir

Phase 3

Hepatitis C, Chronic

DRV + COBI + FTC + TAF FDC

Phase 3

HIV-1

Pegylated interferon alpha-2a

Phase 3

Hepatitis C Virus Genotype-1

Durogesic® (fentanyl transdermal drug delivery system)

Phase 3

Chronic Pain

Paliperidone ER OROS®

Phase 3

Schizophrenia

Canagliflozin

Phase 3

Diabetes Mellitus, Type 2

galantamine ER

Phase 3

Alzheimer's Disease

Ad26.ZEBOV 5*10^10 viral particles (vp)

Phase 3

Healthy

Intravenous immunoglobulins (IVIG)

Phase 3

Thrombocytopenia, Neonatal Alloimmune

methylphenidate

Phase 3

Depressive Disorder, Major

Sirukumab

Phase 3

Arthritis, Rheumatoid

Daratumumab IV

Phase 3

Multiple Myeloma

Paliperidone extended release (ER)

Phase 3

Schizophrenia

Ad26.RSV.PreF-based Vaccine

Phase 3

Respiratory Syncytial Virus Prevention

Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF

Phase 3

Respiratory Syncytial Viruses

D/C/F/TAF

Phase 3

Human Immunodeficiency Virus Type 1

Nesiritide

Phase 3

Heart Decompensation

Fumaric Acid Esters

Phase 3

Psoriasis

Temsirolimus

Phase 3

Mantle Cell Lymphoma

Sofosbuvir

Phase 3

Chronic Hepatitis C

Epo-alpha

Phase 3

Resuscitation

Tapentadol (CG5503) Extended Release (ER)

Phase 3

Pain

Rivaroxaban (Xarelto, BAY59-7939)

Phase 3

Venous Thromboembolism

Morphine

Phase 3

Hysterectomy

oxycodone

Phase 3

Osteoarthritis, Knee

Risperidone, long-acting injectable

Phase 3

Schizophrenia

risperidone; quetiapine

Phase 3

Bipolar Disorder

topiramate, propranolol

Phase 3

Migraine

Enoxaparin

Phase 3

Venous Thromboembolism

VELCADE

Phase 3

Diffuse Large B-Cell Lymphoma

CG5503 IR

Phase 3

Bunionectomy

Acetaminophen

Phase 3

Post Operative Analgesia

oxycodone CR

Phase 3

Joint Diseases

F#13418-158 Eye Drops

Phase 3

Ophthalmic Solutions

tramadol, acetaminophen

Phase 3

Diabetic Neuropathies

risperidone oral tablets

Phase 3

Anxiety Disorders

Risperidone long-acting injectable

Phase 3

Schizophrenia

Bortezomib + Rituximab

Phase 3

Non-Hodgkin's Lymphoma

Epoetin alfa once every two weeks

Phase 3

Anemia

Epoetin alfa once weekly

Phase 3

Anemia

Tapentadol ER

Phase 3

Pain

recombinant human erythropoietin alfa

Phase 3

Infarction, Middle Cerebral Artery

Cyclophosphamide

Phase 3

Mantle Cell Lymphoma

Micronized 17B-estradiol

Phase 3

Atherosclerosis

levofloxacin; amoxicillin/clavulanate

Phase 3

Otitis Media

ICI35,868 (Diprivan) + EES0000645/A (SDS)

Phase 3

Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy

VELCADE Administered by subcutaneous injection

Phase 3

Multiple Myeloma

Risperidone, oral tablets

Phase 3

Bipolar Disorders

levofloxacin, azithromycin, amoxicillin/clavulanate

Phase 3

Bronchitis

ICI35,868 (Diprivan)

Phase 3

Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy

Tapentadol IR (CG5503)

Phase 3

Joint Diseases

Conventional Antiarrhythmic Drug Therapy

Phase 3

Atrial Fibrillation

Tapentadol ER (CG5503)

Phase 3

Joint Diseases

Test acetaminophen

Phase 3

Post-operative Dental Pain

Patent 2032

CG 5503;tapentadol

Phase 3

Osteoarthritis

tapentadol (CG5503) ER

Phase 3

Low Back Pain

levofloxacin

Phase 3

Pneumonia

Rivaroxaban

Phase 3

Atrial Fibrillation

Patent 2044

tapentadol (CG5503) Immediate Release IR

Phase 3

Low Back Pain

Acetaminophen/Naproxen Sodium Fixed Combination

Phase 3

Pain

Paliperidone extended-release

Phase 3

Bipolar Disorder

Risperdal Consta

Phase 3

Bipolar Disorder

Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)

Phase 3

Multiple Myeloma

paliperidone ER Oros

Phase 3

Schizophrenia

Gemcitabine with R115777

Phase 3

Pancreatic Neoplasms

Mebendazole

Phase 3

Healthy Volunteers

Dapoxetine

Phase 3

Erectile Dysfunction

F# 13418-148 Eye Drops

Phase 3

Ophthalmic Solutions

Rivaroxaban 2.5 mg

Phase 3

Acute Coronary Syndrome

Patent 2044

Paliperidone ER

Phase 3

Schizophrenia

topiramate

Phase 3

Essential Tremor

Patent 2040

doripenem

Phase 3

Pneumonia

norelgestromin + ethinyl estradiol

Phase 3

Contraception

Tapentadol extended release (ER)

Phase 3

Diabetic Peripheral Neuropathy

Thalidomide

Phase 3

Multiple Myeloma

CG5503 IR;tapentadol

Phase 3

Arthralgia

Topiramate; Carbamazepine; Valproate

Phase 3

Epilepsy

levofloxacin; imipenem/cilastitin

Phase 3

Nosocomial Pneumonia

Pancrease MT 10.5, or MT 21

Phase 3

Exocrine Pancreatic Insufficiency

Colloidal Oatmeal Cream

Phase 3

Eczema

ivermectin

Phase 3

Lice Infestations

Paliperidone palmitate eq

Phase 3

Schizophrenia

JNJ-90301900 (NBTXR3)

Phase 3

Locally Advanced Head and Neck Squamous Cell Carcinoma

norelgestromin + ethinyl estradiol; mercilon

Phase 3

Contraception

Extended-release galantamine hydrobromide

Phase 3

Schizophrenia

Test naproxen sodium tablet

Phase 3

Post-operative Dental Pain

galantamine

Phase 3

Alzheimer's Disease

Minoxidil Topical Foam

Phase 3

Androgenetic Alopecia

Imonogas

Phase 3

Functional Dyspepsia

rabeprazole

Phase 3

Gastroesophageal Reflux Disease (GERD)

galantamine hydrobromide

Phase 3

Alzheimer Disease

Hydromorphone HCl

Phase 3

Pain

topiramate, phenytoin

Phase 3

Epilepsy

Paliperidone palmitate

Phase 3

Schizophrenia

norelgestromin + ethinyl estradiol; triphasil

Phase 3

Contraception

doripenum

Phase 3

Urinary Tract Infections

acetaminophen extended release

Phase 3

Osteoarthritis

CG5503

Phase 3

Diabetic Neuropathy

Duragesic® (fentanyl) Therapeutic Transdermal System (TTS)

Phase 3

Chronic Pain

CG5503 IR; tapentadol

Phase 3

Osteoarthritis

naproxen

Phase 3

Osteoarthritis, Hip

minoxidil

Phase 3

Androgenetic Alopecia

PDE5I (phosphodiesterase-5 inhibitor)

Phase 3

Erectile Dysfunction

Extended Release OROS® Paliperidone

Phase 3

Schizophrenia

acetaminophen Tablet

Phase 3

Post Operative Dental Pain

Paliperidone

Phase 3

Schizophrenia

Epoetin alfa 3 times weekly/once weekly

Phase 3

Anemia

Tipifarnib;Zarnestra; R115777

Phase 3

Acute Myeloid Leukemia

epoetin alfa

Phase 3

Chronic Kidney Disease

Prucalopride

Phase 3

Constipation

Tapentadol Extended Release

Phase 3

Tumor

Ibrutinib

Phase 3

Leukemia, Lymphocytic, Chronic, B-Cell

TAR-200

Phase 3

Non-Muscle Invasive Bladder Neoplasms

Levetiracetam

Phase 3

Epilepsy

Cilta-cel

Phase 3

Multiple Myeloma

Talquetamab

Phase 3

Multiple Myeloma

TMC435

Phase 3

Hepatitis C

JNJ-77242113

Phase 3

Plaque Psoriasis

Simeprevir

Phase 3

Hepatitis C Virus Infection

Fentanyl

Phase 3

Postherpetic Neuralgia

No treatment

Phase 3

Hepatitis C

JNJ-63723283

Phase 3

Multiple Myeloma

Guselkumab

Phase 3

Psoriasis

Daratumumab

Phase 3

Multiple Myeloma

Ad26.COV2.S

Phase 3

Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

Macitentan

Phase 3

Pulmonary Arterial Hypertension

Fulranumab

Phase 3

Osteoarthritis

Rilpivirine

Phase 3

HIV-1

Amivantamab

Phase 3

Carcinoma, Non-Small-Cell Lung

Seltorexant

Phase 3

Depressive Disorder, Major

Ustekinumab

Phase 3

Crohn Disease

Teclistamab

Phase 3

Multiple Myeloma

R228060

Phase 2

Major Depressive Disorder

JNJ-40411813

Phase 2

Major Depressive Disorder

Experimental Product Colloidal Oatmeal Balm

Phase 2

Atopic Dermatitis

Antipsychotic medication

Phase 2

Schizophrenia

JNJ-73763989

Phase 2

Hepatitis B, Chronic

JNJ-90301900

Phase 2

Carcinoma, Non-Small-Cell Lung

Acetaminophen/naproxen sodium Dose C

Phase 2

Pain

JNJ16269110

Phase 2

Diabetes Mellitus, Type 2

Pseudoephedrine

Phase 2

Allergic Rhinitis

ibuprofen; pseudoephedrine HCl

Phase 2

Enuresis

Ad26.ZEBOV vaccine

Phase 2

Ebola Virus Disease

NNC0142-0002

Phase 2

Inflammation

RSV Vaccine

Phase 2

Healthy

cholecalciferol

Phase 2

Prostate Cancer

Erdafitinib Intravesical Delivery System

Phase 2

Non-Muscle Invasive Bladder Neoplasms

Tapentadol

Phase 2

Pain

Ad26.RSV.preF (1*10^11 vp)

Phase 2

Respiratory Syncytial Viruses

tapentadol HCl

Phase 2

Pain

VELCADE (bortezomib)

Phase 2

Multiple Myeloma

ET743

Phase 2

Breast Neoplasms

JNJ-37822681

Phase 2

Schizophrenia

JNJ-63623872

Phase 2

Influenza A Virus

AL-335

Phase 2

Hepatitis C, Chronic

Apalutamide

Phase 2

Salivary Gland Neoplasms

Acetaminophen/naproxen sodium Dose D

Phase 2

Pain

R092670

Phase 2

Schizophrenia

Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

Phase 2

Carcinoma, Non-Small-Cell Lung

Olomorasib

Phase 2

Carcinoma, Non-Small-Cell Lung

JNJ-41443532

Phase 2

Diabetes Mellitus, Type 2

VX-787

Phase 2

Influenza A

JNJ-39588146/min

Phase 2

Heart Failure

tipifarnib (R115777)

Phase 2

Leukemia, Nonlymphocytic, Acute

JNJ39758979

Phase 2

Asthma

Ad26.RSV.preF

Phase 2

Respiratory Syncytial Virus

Ketoconazole

Phase 2

Neoplasm Metastases

Ad26.Mos.HIV

Phase 2

Healthy

Imipenem/cilastatin

Phase 2

Pneumonia, Ventilator-Associated

JNJ-31001074

Phase 2

Attention Deficit Hyperactivity Disorder

Fluarix

Phase 2

Healthy

JNJ-39588146 5, 15, or/min

Phase 2

Heart Failure

Alimta

Phase 2

Non-Small Cell Lung Cancer

JNJ 40929837

Phase 2

Asthma

Daratumumab Injection

Phase 2

Plasma Cell Disorder

R209130

Phase 2

Schizophrenia

Cetrelimab

Phase 2

Urinary Bladder Neoplasms

JNJ-42847922

Phase 2

Depressive Disorder, Major

Acetaminophen/naproxen sodium Dose A

Phase 2

Pain

R256918

Phase 2

Obesity

Atazanavir (ATV)

Phase 2

HIV Infections

ZARNESTRA, tipifarnib, R115777

Phase 2

Acute Myeloid Leukemia

ExPEC4V (4 : 4 : 4 : 4)

Phase 2

Healthy

TMC207 (bedaquiline)

Phase 2

Tuberculosis, Multidrug-Resistant

JNJ-17166864

Phase 2

Allergic Rhinitis

Acetaminophen (ACE)

Phase 2

Dental Pain

JNJ 49095397

Phase 2

Chronic Obstructive Pulmonary Disease

Escitalopram

Phase 2

Major Depressive Disorder

JNJ-64565111 Dose Level 1

Phase 2

Obesity and Diabetes Mellitus, Type 2

CNTO 1959

Phase 2

Palmoplantaris Pustulosis

Acetaminophen/naproxen sodium Dose B

Phase 2

Pain

PROCRIT (Epoetin alfa)

Phase 2

Anemia

Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)

Phase 2

Multiple Myeloma

Nesiritide (1+0.01)

Phase 2

Heart Failure, Congestive

Acetaminophen/naproxen sodium Dose E

Phase 2

Pain

Oral Dexamethasone

Phase 2

Multiple Myeloma

Siltuximab

Phase 2

Multicentric Castleman's Disease

Blink® Tears eye drops in a multidose bottle

Phase 2

Visual Acuity

Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin

Phase 2

Carcinoma, Non-Small-Cell Lung

T2-18C3 therapeutic antibody

Phase 2

Type 2 Diabetes

Xarelto (Rivaroxaban, BAY59-7939)

Phase 2

Venous Thromboembolism

JNJ-26489112

Phase 2

Photosensitive Epilepsy

naproxen sodium with acetaminophen

Phase 2

Pain

Atomoxetine

Phase 2

Attention Deficit Hyperactivity Disorder

Investigational Lubricating Eye Drop in a Novelia® bottle

Phase 2

Dry Eye

JNJ-39220675

Phase 2

Allergic Rhinitis

JNJ-40346527

Phase 2

Arthritis, Rheumatoid

Yondelis

Phase 2

Liposarcoma

JNJ-64304500

Phase 2

Crohn Disease

NNC 0142-0000-0002

Phase 2

Inflammation

JNJ-39393406

Phase 2

Depression

Amivantamab IV

Phase 2

Advanced or Metastatic Colorectal Cancer

Glucocorticoids

Phase 2

Myositis

JNJ-81201887

Phase 2

Geographic Atrophy

CNTO 2476 3.0 x 10^5 cells

Phase 2

Visual Acuity

Canagliflozin (JNJ-28431754)

Phase 2

Diabetes Mellitus, Type II

RWJ-445380

Phase 2

Rheumatoid Arthritis

R115777

Phase 2

Glioblastoma Multiforme

bortezomib, dexamethasone, thalidomide, and cyclophosphamide

Phase 2

Multiple Myeloma

sIPV

Phase 2

Healthy

bortezomib, dexamethasone, and thalidomide

Phase 2

Multiple Myeloma

JNJ-18038683

Phase 2

Major Depressive Disorder

MVA-Mosaic

Phase 2

Human Immunodeficiency Virus

Daratumumab (Part 1)

Phase 2

Multiple Myeloma

JNJ-53718678

Phase 2

Respiratory Syncytial Virus Infections

Abiraterone

Phase 2

Prostate Cancer

Capmatinib

Phase 2

Carcinoma, Non-Small-Cell Lung

JNJ-42165279

Phase 2

Depressive Disorder

Schizophrenia

4 drugs in this indication

Bipolar Disorder

3 drugs in this indication

Pain

2 drugs in this indication

Multiple Myeloma

2 drugs in this indication

Pneumonia

2 drugs in this indication

Diabetes Mellitus, Type 2

2 drugs in this indication

Low Back Pain

2 drugs in this indication

Atopic Dermatitis

2 drugs in this indication

Heart Failure

2 drugs in this indication

relapsed or refractory multiple myeloma

2 drugs in this indication

Pain relief

2 drugs in this indication

relapsed/refractory multiple myeloma

2 drugs in this indication

Major Depressive Disorder

1 drug in this indication

Ophthalmic Solutions

1 drug in this indication

Acute Coronary Syndrome

1 drug in this indication

Contraception

1 drug in this indication

Post-operative Dental Pain

1 drug in this indication

Chronic Kidney Disease

1 drug in this indication

Healthy Volunteers

1 drug in this indication

Osteoarthritis

1 drug in this indication

Erectile Dysfunction

1 drug in this indication

Atrial Fibrillation

1 drug in this indication

Alzheimer's Disease

1 drug in this indication

Carcinoma, Non-Small-Cell Lung

1 drug in this indication

Enuresis

1 drug in this indication

Pancreatic Neoplasms

1 drug in this indication

Gastroesophageal Reflux

1 drug in this indication

Essential Tremor

1 drug in this indication

recurrent or metastatic head and neck cancer

1 drug in this indication

Sprains and Strains

1 drug in this indication

Diabetic Peripheral Neuropathy

1 drug in this indication

SLE (Systemic Lupus Erythematosus)

1 drug in this indication

depression

1 drug in this indication

Leukemia, Nonlymphocytic, Acute

1 drug in this indication

plaque psoriasis in adults and adolescents

1 drug in this indication

relapsed/refractory multiple myeloma after at least one prior therapy

1 drug in this indication

over-the-counter treatment of pain

1 drug in this indication

plaque psoriasis

1 drug in this indication

Asthma

1 drug in this indication

newly diagnosed multiple myeloma (NDMM)

1 drug in this indication

axial psoriatic arthritis

1 drug in this indication

Arthralgia

1 drug in this indication

High-risk localized prostate cancer

1 drug in this indication

high-risk prostate cancer (perioperative treatment with ADT before and after surgery)

1 drug in this indication

psoriatic arthritis

1 drug in this indication

Sjögren's disease

1 drug in this indication

BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

1 drug in this indication

Recurrent head and neck cancer after prior chemotherapy and immunotherapy

1 drug in this indication

head and neck cancer

1 drug in this indication

Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)

1 drug in this indication

Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed on or after platinum-based chemotherapy

1 drug in this indication

Recurrent or metastatic head and neck cancer (second-line)

1 drug in this indication

Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after progression on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody

1 drug in this indication

Advanced head and neck cancer

1 drug in this indication

Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)

Frequently asked questions

What is in Johnson & Johnson's drug pipeline?→

CatalystAlert tracks 272 drug candidates in Johnson & Johnson's (JNJ) pipeline across Phase 3, Phase 2. Its lead program is Nipocalimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Johnson & Johnson's next FDA catalyst?→

Johnson & Johnson's (JNJ) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track JNJ biotech catalysts?→

Add JNJ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Johnson & Johnson's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply